Kailera Therapeutics (NASDAQ:KLRA) Stock Price Up 6.6% – Time to Buy?

Kailera Therapeutics, Inc. (NASDAQ:KLRA) shares shot up 6.6% during mid-day trading on Monday . The company traded as high as $19.21 and last traded at $19.13. Approximately 341,212 shares were traded during trading, a decline of 51% from the average daily volume of 700,079 shares. The stock had previously closed at $17.94.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on KLRA shares. Weiss Ratings assumed coverage on Kailera Therapeutics in a research note on Friday. They issued a “sell (d)” rating for the company. JPMorgan Chase & Co. initiated coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They set an “overweight” rating and a $30.00 price objective for the company. William Blair assumed coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating for the company. TD Cowen began coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $57.00 target price for the company. Finally, Wall Street Zen lowered shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.75.

Kailera Therapeutics Trading Down 3.7%

The stock’s 50 day moving average is $19.37. The stock has a market cap of $2.31 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). As a group, research analysts forecast that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current year.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.